Cambridge, Mass. – January 4, 2019 – Generation Bio, a company developing the first genetic medicines that can be re-dosed and titrated to effect for a lifetime of benefit, today announced the company will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 8, 2019.
President and Chief Executive Officer Geoff McDonough, M.D. will provide an overview of the company and anticipated milestones for 2019.
Date: Tuesday, January 8, 2019
Time: 8:30 a.m. PT
Location: Westin St. Francis Hotel, Elizabethan C
About Generation Bio
Generation Bio is a biotechnology company developing a breakthrough class of genetic medicines to enable a new generation of people to live unaffected by inherited disease. The company is using its proprietary ceDNA platform to create gene therapies with drug-like properties – delivering durable gene expression with the ability to re-dose for individual patient titration and for the potential to sustain effect over a lifetime. Generation Bio was founded and launched by Atlas Venture and is headquartered in Cambridge, Mass. For more information, please visit www.generationbio.com or follow @generationbio.
Stern Investor Relations
Marissa Picerno, Ten Bridge Communications